Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects
Cardiovascular disease remains the leading cause of death and disability in advanced countries. Stem cell transplantation has emerged as a promising therapeutic strategy for acute and chronic ischemic cardiomyopathy. The current status of stem cell therapies for patients with myocardial infarction i...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/63288/1/Stem%20cell%20therapies%20for%20myocardial%20infarction%20in%20clinical%20trials.pdf |
| _version_ | 1825932578759114752 |
|---|---|
| author | Higuchi, Akon Ku, Nien-Ju Tseng, Yeh-Chia Pan, Chih-Hsien Li, Hsing-Fen Kumar, S. Suresh Ling, Qing-Dong Chang, Yung Alarfaj, Abdullah A. Munusamy, Murugan A. Benelli, Giovanni Murugan, Kadarkarai |
| author_facet | Higuchi, Akon Ku, Nien-Ju Tseng, Yeh-Chia Pan, Chih-Hsien Li, Hsing-Fen Kumar, S. Suresh Ling, Qing-Dong Chang, Yung Alarfaj, Abdullah A. Munusamy, Murugan A. Benelli, Giovanni Murugan, Kadarkarai |
| author_sort | Higuchi, Akon |
| collection | UPM |
| description | Cardiovascular disease remains the leading cause of death and disability in advanced countries. Stem cell transplantation has emerged as a promising therapeutic strategy for acute and chronic ischemic cardiomyopathy. The current status of stem cell therapies for patients with myocardial infarction is discussed from a bioengineering and biomaterial perspective in this review. We describe (a) the current status of clinical trials of human pluripotent stem cells (hPSCs) compared with clinical trials of human adult or fetal stem cells, (b) the gap between fundamental research and application of human stem cells, (c) the use of biomaterials in clinical and pre-clinical studies of stem cells, and finally (d) trends in bioengineering to promote stem cell therapies for patients with myocardial infarction. We explain why the number of clinical trials using hPSCs is so limited compared with clinical trials using human adult and fetal stem cells such as bone marrow-derived stem cells. |
| first_indexed | 2024-03-06T09:44:11Z |
| format | Article |
| id | upm.eprints-63288 |
| institution | Universiti Putra Malaysia |
| language | English |
| last_indexed | 2024-03-06T09:44:11Z |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | upm.eprints-632882018-09-26T01:51:14Z http://psasir.upm.edu.my/id/eprint/63288/ Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects Higuchi, Akon Ku, Nien-Ju Tseng, Yeh-Chia Pan, Chih-Hsien Li, Hsing-Fen Kumar, S. Suresh Ling, Qing-Dong Chang, Yung Alarfaj, Abdullah A. Munusamy, Murugan A. Benelli, Giovanni Murugan, Kadarkarai Cardiovascular disease remains the leading cause of death and disability in advanced countries. Stem cell transplantation has emerged as a promising therapeutic strategy for acute and chronic ischemic cardiomyopathy. The current status of stem cell therapies for patients with myocardial infarction is discussed from a bioengineering and biomaterial perspective in this review. We describe (a) the current status of clinical trials of human pluripotent stem cells (hPSCs) compared with clinical trials of human adult or fetal stem cells, (b) the gap between fundamental research and application of human stem cells, (c) the use of biomaterials in clinical and pre-clinical studies of stem cells, and finally (d) trends in bioengineering to promote stem cell therapies for patients with myocardial infarction. We explain why the number of clinical trials using hPSCs is so limited compared with clinical trials using human adult and fetal stem cells such as bone marrow-derived stem cells. Nature Publishing Group 2017-10 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/63288/1/Stem%20cell%20therapies%20for%20myocardial%20infarction%20in%20clinical%20trials.pdf Higuchi, Akon and Ku, Nien-Ju and Tseng, Yeh-Chia and Pan, Chih-Hsien and Li, Hsing-Fen and Kumar, S. Suresh and Ling, Qing-Dong and Chang, Yung and Alarfaj, Abdullah A. and Munusamy, Murugan A. and Benelli, Giovanni and Murugan, Kadarkarai (2017) Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects. Laboratory Investigation, 97. 1167 - 1179. ISSN 0023-6837; ESSN: 1530-0307 10.1038/labinvest.2017.100 |
| spellingShingle | Higuchi, Akon Ku, Nien-Ju Tseng, Yeh-Chia Pan, Chih-Hsien Li, Hsing-Fen Kumar, S. Suresh Ling, Qing-Dong Chang, Yung Alarfaj, Abdullah A. Munusamy, Murugan A. Benelli, Giovanni Murugan, Kadarkarai Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects |
| title | Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects |
| title_full | Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects |
| title_fullStr | Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects |
| title_full_unstemmed | Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects |
| title_short | Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects |
| title_sort | stem cell therapies for myocardial infarction in clinical trials bioengineering and biomaterial aspects |
| url | http://psasir.upm.edu.my/id/eprint/63288/1/Stem%20cell%20therapies%20for%20myocardial%20infarction%20in%20clinical%20trials.pdf |
| work_keys_str_mv | AT higuchiakon stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT kunienju stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT tsengyehchia stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT panchihhsien stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT lihsingfen stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT kumarssuresh stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT lingqingdong stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT changyung stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT alarfajabdullaha stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT munusamymurugana stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT benelligiovanni stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects AT murugankadarkarai stemcelltherapiesformyocardialinfarctioninclinicaltrialsbioengineeringandbiomaterialaspects |